Copenhagen, 2015-05-29 14:00 CEST (GLOBE NEWSWIRE) -- 29 May 2015 – Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) will participate and present to the investor community at the following four conferences in June 2015, taking place in New York, Denmark, Boston and London, respectively.
- Jefferies global Healthcare Conference, New York (1 – 4 June)
Date and time of Zealand’s presentation: Thursday 4 June at 8.30am ET. The company’s management will also host one-on-one investor meetings at the conference.
The presentation will be audio cast live via the following link, http://wsw.com/webcast/jeff88/zeal, accessible also from the Investor section of Zealand’s website (www.zealandpharma.com).
- InvestorDagen, Danish Shareholders Association, Aarhus, Denmark (2 June)
Date and time of Zealand’s presentation: Tuesday 2 June at 12.50pm CET
- Zealand Breakfast presentation at the Annual Scientific Sessions of the American Diabetes Association, ADA, in Boston (5 – 9 June)
Date and time of the breakfast meeting: Monday 8 June, at 6:30am EDT
- Citi European Healthcare One-on-One Conference, London (15-16 June)
Zealand will host one-on-one and group meetings with investors on Monday 15 June 2015.
At the above events, members of Zealand’s executive management will give an update on the most recent milestones and present the overall status for the company’s pipeline of proprietary peptide therapeutics as well as for the portfolio of partnered medicines and development projects, as the company is moving through a catalyst year 2015.
No new financial or other material new information relating to Zealand will be disclosed at the above listed events.
●●●●●
For further information, please contact:
Hanne Leth Hillman, Senior Vice President for Investor Relations & Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com
About Zealand Pharma
Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and possesses in-house competences in clinical trial design and management with a therapeutic focus on metabolic diseases and acute care indications. The company is advancing a pipeline of novel wholly-owned medicines alongside a partnered product and development portfolio.
Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as Lyxumia® and in Phase III development as a single-injection combination with Lantus® (LixiLan), both under a global license agreement with Sanofi. US regulatory submission of Lyxumia® is planned for Q3 2015 and US/EU regulatory submissions for LixiLan in Q4 2015.
Zealand’s wholly-owned pipeline include danegaptide (prevention of Ischemic Reperfusion Injury) in Phase II and the stable glucagon analogue, ZP4207 in two Phase I trials as a single-use rescue pen (severe hypoglycemia) and a multiple-dose version (mild to moderate hypoglycemia) as well as several preclinical peptide therapeutics. Partnering represents an important component of strategy to leverage in-house expertise, share development risk in large clinical trials, provide funding and commercialize the company’s products. Zealand currently has global license agreements and partnerships with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.
For further information: www.zealandpharma.com Follow us on Twitter @ZealandPharma
